A Life Transformed
A groundbreaking clinical trial is making international headlines: for the first time, a woman with Type 1 diabetes has been able to stop taking insulin entirely after receiving a single dose of manufactured stem cells. This remarkable case, recently published in the New England Journal of Medicine, could signal a new era for diabetes care and is being hailed as a milestone in regenerative medicine1.
Amanda Smith, a 36 year old nurse and mother from London, Ontario, had struggled for years with the daily burden of Type 1 diabetes, including the constant threat of dangerous low blood sugar episodes. Diagnosed at age 25, Amanda lived with the fear of sudden hypoglycemia and the risk of diabetic coma. That changed after she participated in a study using experimental stem cells designed to grow in the liver and become insulin-producing islet cells, essentially replacing the function of the pancreas.
“I get emotional because I’m free from those handcuffs … I don’t have that looming over me every day,” Amanda told reporters, describing the day she stopped taking insulin as “history now”
The Science Behind the Breakthrough
The study, led by Dr. Trevor Reichman, Surgical Director of the Pancreas and Islet Cell Transplant Program at Toronto’s University Health Network, involved 12 patients. Ten of them, including Amanda, were able to stop insulin injections for at least a year, and all were spared from severe hypoglycemia. The stem cells, developed by Boston-based Vertex Pharmaceuticals, were derived from embryonic tissue and grown in large quantities before being infused into patients’ livers. There, they matured into a full array of hormone-producing cells that regulate blood sugar in real time, mirroring the natural function of pancreatic islet cells.
“It’s never been done before in history,” said Dr. Michael Thompson, Director of the Vancouver General Diabetes Centre. “It’s the first time they have achieved high enough levels of insulin in patients using a stem cell product. It’s a big advance”1.
Promise and Caution
While the results are extraordinary, the therapy is not without risks. Patients must take lifelong immunosuppressive drugs to prevent their immune systems from attacking the new cells. These medications carry their own dangers, including higher risks of infections, some cancers, and high blood pressure. In the study, two participants died—one likely due to complications from immunosuppression, highlighting the need for careful monitoring
Amanda, however, says the tradeoff is worth it: “Taking a couple of pills three times a day is nothing. I take it with breakfast, lunch, and dinner. It’s easy. No comparison, none,” she said.
A New Frontier for Diabetes Care
This stem cell therapy, now called Zimislecel (formerly VX-880), offers hope for a future where insulin injections—and the constant vigilance they require may no longer be necessary for many people with Type 1 diabetes. Unlike earlier approaches that relied on donor islet cells (limited by organ availability), manufactured stem cells could provide a limitless supply, pushing the boundaries of what’s possible in diabetes treatment.
Researchers are now working to refine the therapy, aiming to eliminate the need for immunosuppression through genetic engineering or encapsulation techniques. Meanwhile, the trial is expanding to include more patients in Canada and the U.S., with the hope of confirming these early, transformative results
=
